Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

Eli Lilly is significantly increasing the list price of its GLP-1 drug Mounjaro in the UK by 170% to £330, with similar adjustments anticipated across other European markets, aligning with a "most favored nation" pricing concept aimed at optimizing global revenue. Bank of America maintains a Buy rating and $900 price target on Lilly, asserting that U.S. GLP-1 pricing is unlikely to pressure margins, despite investor nervousness regarding pricing stability, as any potential concessions would be volume-accretive and net positive for the company. This aggressive ex-U.S. pricing strategy underscores the escalating competition in the lucrative obesity drug market.

Analysis

Eli Lilly is executing an aggressive international pricing strategy for its GLP-1 drug Mounjaro, exemplified by a 170% list price increase in the United Kingdom to £330. This move, with similar adjustments expected across Europe, is intended to align with a "most favored nation" pricing concept, effectively raising ex-U.S. prices where patients often pay out-of-pocket. Bank of America Securities addresses a key investor concern by asserting that there is little risk of this strategy negatively impacting U.S. margins. The firm's analysis suggests that Lilly's domestic initiatives, such as the 'Lilly Direct' channel, are primarily designed to bypass pharmacy benefit managers (PBMs) and maintain existing net price levels, rather than enact meaningful price cuts. BofA concludes that any potential U.S. price concessions would likely be volume-accretive and ultimately net positive for Lilly's P&L. This perspective underpins BofA's reiterated Buy rating and $900 price target, which is based on the rationale of outsized growth at a reasonable valuation, despite investor nervousness surrounding GLP-1 pricing stability.

Key Decisions for Investors

• Investors may consider the aggressive ex-U.S. pricing as a validation of Lilly's market power in the GLP-1 space, potentially de-risking concerns over U.S. pricing pressure and reinforcing the long-term revenue growth thesis.
• It is prudent to monitor the competitive response from Novo Nordisk, as Lilly's pricing actions are likely to intensify the battle for market share in the lucrative global obesity drug market.
• Investors should track the implementation of the 'most favored nation' pricing concept and its reception in European markets, as its success will be a key determinant of future international revenue streams.
• Given the significant upside implied by Bank of America's $900 price target compared to the current price of ~$690, growth-oriented investors might view current levels as an attractive entry point, contingent on their agreement with the analyst's margin stability assessment.